Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Doxorubicin · Doxil, Doxorubicin Hydrochloride

Small molecule · Inhibitor of DNA topoisomerase II (TOP2A) · developed by Pfizer

Approved FDA, Aug 1974
15 Registered trials

What is Doxorubicin?

Doxorubicin is an approved small-molecule drug studied in Cancer, Pancreatic Cancer, Sarcoma.

At a glance

Also known as
Doxil, Doxorubicin Hydrochloride, Adriamycin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin
Drug type
Small molecule
Targets
DNA topoisomerase II (TOP2A)
Mechanism
Inhibitor of DNA topoisomerase II (TOP2A)
Pathways
DNA replication inhibition, nucleotide intercalation, free radical formation and lipid peroxidation
Therapy area
Oncology
Developer
Pfizer
In trials of
ACTU, ADAG, ADCT, AGEN, ALXO, BYSI, CELC, FATE, IBRX, IMNN
FDA status
Approved as Doxil, Doxorubicin Hydrochloride (August 7, 1974), NDA050467 · FDA label

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03294577 Phase 3 Chemotherapy-induced Neutropenia Unknown BYSI
NCT05864534 Phase 2 Newly Diagnosed Glioblastoma Active not recruiting AGEN
NCT05600686 Phase 2 Double-Expressor Lymphoma Active not recruiting ADCT
NCT05467670 Phase 2 Ovarian Cancer Active not recruiting ALXO
NCT05275777 Phase 1/2 HER2-negative Breast Cancer Active not recruiting ADAG
NCT05099666 Phase 1/2 Advanced Soft-tissue Sarcoma Active not recruiting JAZZ
NCT04028063 Phase 2 Metastatic Soft Tissue Sarcoma Active not recruiting AGEN
NCT03678883 Phase 2 Cancer Active not recruiting ACTU
NCT03554109 Phase 2 Triple Negative Breast Cancer (TNBC) Withdrawn IBRX
NCT03412643 Phase 2 HER2-negative Breast Cancer Unknown CELC
NCT01464593 Phase 2 Colon Cancer Liver Metastasis Terminated IMNN
NCT01008150 Phase 2 Breast Cancer Completed PBYI
NCT00718484 Phase 2 Soft Tissue Sarcoma Terminated TCRT
NCT05934097 Phase 1 Diffuse Large B Cell Lymphoma Withdrawn FATE
NCT04852367 Phase 1 Pancreatic Ductal Adenocarcinoma Withdrawn IMNN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CancerNeoplasm MetastasisNeoplasm of BoneNeoplasm of LungNeoplasm, BreastNeoplasms PancreaticNeoplasms,ColorectalPancreatic AdenocarcinomaPancreatic CancerRefractory CancerRefractory NeoplasmRefractory Non-Hodgkin LymphomaRenal CancerResistant Cancer

Other drugs acting on TOP2A

Amrubicin Phase 3 Berubicin Phase 2 Camsirubicin Phase 1 IMX-110 Phase 1/2 Pegylated Liposomal Doxorubicin Phase 3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.